Nanocomplexes from RGD-modified generation 1.0 polyamidoamine based copolymers used for intravascular gene release to...

Area of Science:

• Biomaterials Science
• Gene Therapy
• Cardiovascular Research

Background:

• Restenosis remains a significant complication after vascular interventions.
• Targeted gene delivery systems are crucial for effective therapeutic strategies.
• Polyamidoamine (PAMAM) copolymers offer potential as gene vectors.

Purpose of the Study:

• To validate the efficacy of RGD-modified polyamidoamine (PAMAM G1) nanocomplexes for preventing restenosis.
• To evaluate the properties and gene delivery capabilities of these novel nanocomplexes.

Main Methods:

• Synthesis and characterization of PAMAM G1-based copolymers (PGP) and RGD-modified PGP (PGP-RGD).
• Evaluation of nanocomplex properties including size, zeta potential, and cytotoxicity.
• Assessment of pDNA binding ability and transfection efficiency in human umbilical vein endothelial cells.
• Intravascular VEGF165 release tests and assessment of arterial patency in vivo.

Main Results:

• PGP-RGD1 (2.6% grafting rate) showed reduced cytotoxicity and improved pDNA binding.
• Nanocomplexes ranged from 80-160 nm with zeta potentials of 3-20 mV.
• PGP-RGD1 complexes exhibited higher transfection efficiency in endothelial cells compared to PGP complexes.
• The PGP-RGD1 group demonstrated improved arterial patency and gene expression levels.

Conclusions:

• PGP-RGD1 nanocomplexes represent a promising targeted gene vector for restenosis prevention.
• The RGD modification enhances the efficacy and targeting of PAMAM G1-based gene delivery systems.